Skip to Content

Lybrel Approval History

  • FDA approved: Yes (First approved May 22nd, 2007)
  • Brand name: Lybrel
  • Generic name: levonorgestrel and ethinyl estradiol
  • Dosage form: Low Dose Continuous Regimen
  • Company: Wyeth Pharmaceuticals Inc.
  • Treatment for: Birth Control

Lybrel (levonorgestrel and ethinyl estradiol) is a low-dose combination contraceptive pill taken continuously (without a pill-free interval) and over time may eliminate scheduled menstrual periods. Lybrel is indicated for the prevention of pregnancy.

Development History and FDA Approval Process for Lybrel

May 23, 2007Approval FDA Approves Lybrel, First Low Dose Combination Oral ContraceptiveOffering Women the Opportunity to Be Period-Free Over Time
Jun 28, 2006Wyeth Receives Approvable Letter From the FDA for Lybrel
Jul 27, 2005Wyeth's New Drug Application for New Oral Contraceptive With Uninterrupted Dosing Regimen Accepted for Filing at FDA

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.